TB-500
TB-500 is a synthetic fraction of the protein thymosin beta-4, which is present in virtually all human and animal cells. It promotes healing, muscle building, and flexibility.
Common Dosage
2mg - 2.5mg twice weekly
Category
Recovery
- Muscle growth
- Improved flexibility
- Reduced inflammation
- Tissue regeneration
TB-500 is a synthetic fragment of Thymosin Beta-4 (Tβ4), a 43-amino-acid protein ubiquitously expressed in virtually every nucleated cell in the human body. Thymosin Beta-4 was first identified in the 1960s during early immunology research on thymic hormones. The TB-500 fragment corresponds to the actin-binding domain of Tβ4 and is responsible for a significant portion of its regenerative activity. Equine sports medicine was an early adopter, with TB-500 becoming a subject of significant attention in performance horse research before migrating into human research circles.
TB-500 promotes healing primarily through actin regulation — it sequesters G-actin monomers, enabling rapid cell migration to injury sites. It upregulates cell-surface receptors for growth factors, stimulates angiogenesis (new blood vessel formation), and downregulates inflammatory signaling. Its systemic distribution — unlike many locally-acting peptides — means it works throughout the body regardless of injection site.
- Muscle fiber repair following tears or high-load training
- Tendon and ligament injury recovery, particularly in combination with BPC-157
- Cardiac tissue repair following ischemic injury (well-studied in rodent and porcine models)
- Wound healing including chronic non-healing wounds
- Corneal and ocular tissue repair
- Neurological tissue repair and remyelination research
- Flexibility and range of motion improvement in chronic connective tissue dysfunction
Muscle Tear Recovery Stack
The BPC-157 + TB-500 combination has become a gold standard in the self-research community for injury recovery. Users with partial rotator cuff tears have reported functional improvement in 6–8 weeks that previously plateaued with physical therapy alone. The systemic nature of TB-500 is cited as key — it reaches the injury regardless of injection location.
Cardiac Research
Animal studies have demonstrated that TB-500 (as Tβ4) can stimulate cardiac progenitor cell migration into damaged heart muscle following MI. In a pig model of heart attack, Tβ4 treatment was associated with measurable improvement in ejection fraction and reduced scar tissue formation.
Chronic Low Back Pain
Practitioners have reported cases where individuals with chronic disc-related back pain noted reduced inflammation and improved mobility after 4–6 week TB-500 courses. The anti-inflammatory mechanism combined with connective tissue support provides a plausible pathway.
- No human clinical trials for the specific TB-500 fragment — human data extrapolated from Tβ4 research
- Potential pro-angiogenic effects are a theoretical concern in individuals with active cancer or undiagnosed malignancy
- Equine anti-doping authorities have flagged TB-500 due to its performance-enhancement potential — relevant for competitive athletes
- Storage and handling requirements (cold chain) affect potency; improper storage degrades efficacy
- Interaction with cardiac remodeling pathways should be considered by those with existing heart conditions
- Tiredness
- Headache